Analyzing the Uveitis Disease Landscape: Prevalence, Impact, and Treatments

Health Apr 21, 2025 21 Add to Reading List

Uveitis is a serious inflammatory condition affecting the uveal tract—the eye’s middle layer, comprising the iris, ciliary body, and choroid. This inflammation may also involve adjacent structures like the retina, cornea, sclera, optic nerve, and vitreous body. Most commonly triggered by immune responses to infections or autoimmune diseases, uveitis is a major contributor to vision loss worldwide. It accounts for 10–15% of all blindness cases, with more than one-third of patients experiencing some level of visual impairment. Anterior uveitis is the most prevalent form, making up nearly 50% of all cases, whereas posterior uveitis is the least frequent.

???? Dive deeper with the full Uveitis Market Report to stay informed on pipeline therapies, epidemiology forecasts, and competitive intelligence

Epidemiological Breakdown (2020–2034, 7MM)

Total diagnosed prevalent cases
Distribution by uveitis type
Anatomical classification-based data
Etiology-wise diagnosed cases

Key Epidemiology Insights
In 2022, around 1 million people were living with diagnosed uveitis across the 7 major markets (7MM). The United States represented a significant portion, with 378,000 cases—around 37.5% of the total. Spain had the lowest burden, contributing roughly 7%. In the U.S., noninfectious uveitis (NIU) was far more common than infectious uveitis (IU), with 344,587 NIU cases versus 33,695 IU cases, both expected to rise through 2034.

Uveitis Market Snapshot
As of 2022, the uveitis market across the 7MM was valued at approximately USD 1.4 billion.

Market Growth Drivers

The introduction of novel therapies with targeted mechanisms and improved delivery platforms is reshaping treatment paradigms.
Advancements in the understanding of immune pathways and disease triggers are enabling precision-based treatment strategies.

Barriers to Optimal Care

Side effects and tolerability issues limit the use of many existing treatments for long-term management.
A lack of sufficient clinical trial data and reliance on off-label therapies hinder standardization in care.

Promising Therapies in Development
Several new drugs are in various stages of clinical trials or regulatory review, such as: